Read by QxMD icon Read

Breast Cancer Research: BCR

Liu Yang, Yanhua Tian, Wei Sun Leong, Heng Song, Wei Yang, Meiqi Wang, Xinle Wang, Jing Kong, Baoen Shan, Zhengchuan Song
BACKGROUND: Drug resistance of paclitaxel (TAX), the first-line chemotherapy drug for breast cancer, was reported to develop in 90% of patients with breast cancer, especially metastatic breast cancer. Investigating the mechanism of TAX resistance of breast cancer cells and developing the strategy improving its therapeutic efficiency are crucial to breast cancer cure. METHODS AND RESULTS: We here report an elegant nanoparticle (NP)-based technique that realizes efficient breast cancer treatment of TAX...
September 18, 2018: Breast Cancer Research: BCR
Mustapha Abubakar, Hyuna Sung, Devi Bcr, Jennifer Guida, Tieng Swee Tang, Ruth M Pfeiffer, Xiaohong R Yang
BACKGROUND: Limited evidence, mostly from studies in Western populations, suggests that the prognostic effects of lifestyle-related risk factors may be molecular subtype-dependent. Here, we examined whether pre-diagnostic lifestyle-related risk factors for breast cancer are associated with clinical outcomes by molecular subtype among patients from an understudied Asian population. METHODS: In this population-based case series, we evaluated breast cancer risk factors in relation to 10-year all-cause mortality (ACM) and 5-year recurrence by molecular subtype among 3012 women with invasive breast cancer in Sarawak, Malaysia...
September 18, 2018: Breast Cancer Research: BCR
Pin Gao, Xiang Wang, Ying Jin, Wenquan Hu, Yajun Duan, Aiping Shi, Ye Du, Dong Song, Ming Yang, Sijie Li, Bing Han, Gang Zhao, Hongquan Zhang, Zhimin Fan, Qing Robert Miao
BACKGROUNDS: Tamoxifen is typically used to treat patients with estrogen receptor alpha (ERα)-positive breast cancer. However, 30% of these patients gain acquired resistance to tamoxifen during or after tamoxifen treatment. As a Ras modulator, Nogo-B receptor (NgBR) is required for tumorigenesis through the signaling crosstalk with epidermal growth factor (EGF) receptor (EGFR)-mediated pathways. NgBR is highly expressed in many types of cancer cells and regulates the sensitivity of hepatocellular carcinoma to chemotherapy...
September 12, 2018: Breast Cancer Research: BCR
Nicholas A Zumwalde, Jill D Haag, Michael N Gould, Jenny E Gumperz
BACKGROUND: Antimicrobial T cells play key roles in the disease progression of cancers arising in mucosal epithelial tissues, such as the colon. However, little is known about microbe-reactive T cells within human breast ducts and whether these impact breast carcinogenesis. METHODS: Epithelial ducts were isolated from primary human breast tissue samples, and the associated T lymphocytes were characterized using flow cytometric analysis. Functional assays were performed to determine T-cell cytokine secretion in response to bacterially treated human breast carcinoma cells...
September 12, 2018: Breast Cancer Research: BCR
Patrick Schöffski, Sara Cresta, Ingrid A Mayer, Hans Wildiers, Silvia Damian, Steven Gendreau, Isabelle Rooney, Kari M Morrissey, Jill M Spoerke, Vivian W Ng, Stina M Singel, Eric Winer
BACKGROUND: This phase Ib study (NCT00960960) evaluated pictilisib (GDC-0941; pan-phosphatidylinositol 3-kinase inhibitor) plus paclitaxel, with and without bevacizumab or trastuzumab, or in combination with letrozole, in patients with locally recurrent or metastatic breast cancer. METHODS: This was a three-part multischedule study. Patients in parts 1 and 2, which comprised 3 + 3 dose escalation and cohort expansion stages, received pictilisib (60-330 mg) plus paclitaxel (90 mg/m2 ) with and without bevacizumab (10 mg/kg) or trastuzumab (2-4 mg/kg)...
September 5, 2018: Breast Cancer Research: BCR
Aya Asano, Shigeto Ueda, Ichiei Kuji, Tomohiko Yamane, Hideki Takeuchi, Eiko Hirokawa, Ikuko Sugitani, Hiroko Shimada, Takahiro Hasebe, Akihiko Osaki, Toshiaki Saeki
After the publication of this article [1], we noticed that in Fig. 2, the survival curve images (C and D, lower panel) were incorrect. The corrected Fig. 2 is presented below. The correction does not affect in any our results and conclusions.
September 5, 2018: Breast Cancer Research: BCR
Roberto R Rosato, Daniel Dávila-González, Dong Soon Choi, Wei Qian, Wen Chen, Anthony J Kozielski, Helen Wong, Bhuvanesh Dave, Jenny C Chang
BACKGROUND: Breast cancer has been considered not highly immunogenic, and few patients benefit from current immunotherapies. However, new strategies are aimed at changing this paradigm. In the present study, we examined the in vivo activity of a humanized anti-programmed cell death protein 1 (anti-PD-1) antibody against triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) tumor models. METHODS: To circumvent some of the limitations posed by the lack of appropriate animal models in preclinical studies of immunotherapies, partially human leukocyte antigen-matched TNBC PDX tumor lines from our collection, as well as human melanoma cell lines, were engrafted in humanized nonobese diabetic/severe combined immunodeficiency IL2Rγnull (hNSG) mice obtained by intravenous injection of CD34+ hematopoietic stem cells into nonlethally irradiated 3-4-week-old mice...
September 5, 2018: Breast Cancer Research: BCR
Mélanie Bousquenaud, Flavia Fico, Giovanni Solinas, Curzio Rüegg, Albert Santamaria-Martínez
BACKGROUND: Obesity is a strong predictor of poor prognosis in breast cancer, especially in postmenopausal women. In particular, tumors in obese patients tend to seed more distant metastases, although the biology behind this observation remains poorly understood. METHODS: To elucidate the effects of the obese microenvironment on metastatic spread, we ovariectomized C57BL/6 J female mice and fed them either a regular diet (RD) or a high-fat diet (HFD) to generate a postmenopausal diet-induced obesity model...
September 4, 2018: Breast Cancer Research: BCR
Zuzana Koledova, Beatrice A Howard, Johanna Englund, Karsten Bach, Mohammed Bentires-Alj, Eva Gonzalez-Suarez
The European Network for Breast Development and Cancer (ENBDC), a worldwide network ( ), celebrated its tenth anniversary with a fantastic meeting last March 15-17, 2018 in Weggis with 76 attendees.
September 4, 2018: Breast Cancer Research: BCR
Alexey A Leontovich, Mohammad Jalalirad, Jeffrey L Salisbury, Lisa Mills, Candace Haddox, Mark Schroeder, Ann Tuma, Maria E Guicciardi, Luca Zammataro, Mario W Gambino, Angela Amato, Aldo Di Leonardo, James McCubrey, Carol A Lange, Minetta Liu, Tufia Haddad, Matthew Goetz, Judy Boughey, Jann Sarkaria, Liewei Wang, James N Ingle, Evanthia Galanis, Antonino B D'Assoro
BACKGROUND: Development of distant metastases involves a complex multistep biological process termed the invasion-metastasis cascade, which includes dissemination of cancer cells from the primary tumor to secondary organs. NOTCH developmental signaling plays a critical role in promoting epithelial-to-mesenchymal transition, tumor stemness, and metastasis. Although all four NOTCH receptors show oncogenic properties, the unique role of each of these receptors in the sequential stepwise events that typify the invasion-metastasis cascade remains elusive...
September 4, 2018: Breast Cancer Research: BCR
Tian Du, Matthew J Sikora, Kevin M Levine, Nilgun Tasdemir, Rebecca B Riggins, Stacy G Wendell, Bennett Van Houten, Steffi Oesterreich
BACKGROUND: Invasive lobular breast carcinoma (ILC) is a histological subtype of breast cancer that is characterized by loss of E-cadherin and high expression of estrogen receptor alpha (ERα). In many cases, ILC is effectively treated with adjuvant aromatase inhibitors (AIs); however, acquired AI resistance remains a significant problem. METHODS: To identify underlying mechanisms of acquired anti-estrogen resistance in ILC, we recently developed six long-term estrogen-deprived (LTED) variant cell lines from the human ILC cell lines SUM44PE (SUM44; two lines) and MDA-MB-134VI (MM134; four lines)...
September 4, 2018: Breast Cancer Research: BCR
Richard Buus, Belinda Yeo, Adam R Brentnall, Marie Klintman, Maggie Chon U Cheang, Komel Khabra, Ivana Sestak, Qiong Gao, Jack Cuzick, Mitch Dowsett
BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year follow-up separately are more prognostic than a single signature optimised for 10 years. METHODS: Genes previously identified as prognostic or associated with endocrine resistance were tested in publicly available microarray data set using Cox regression of 747 ER+/HER2- samples from post-menopausal patients treated with 5 years of endocrine therapy...
September 4, 2018: Breast Cancer Research: BCR
Jia Wu, Xuejie Li, Xiaodong Teng, Daniel L Rubin, Sandy Napel, Bruce L Daniel, Ruijiang Li
BACKGROUND: We sought to investigate associations between dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) features and tumor-infiltrating lymphocytes (TILs) in breast cancer, as well as to study if MRI features are complementary to molecular markers of TILs. METHODS: In this retrospective study, we extracted 17 computational DCE-MRI features to characterize tumor and parenchyma in The Cancer Genome Atlas cohort (n = 126). The percentage of stromal TILs was evaluated on H&E-stained histological whole-tumor sections...
September 3, 2018: Breast Cancer Research: BCR
Holly Holliday, Laura A Baker, Simon R Junankar, Susan J Clark, Alexander Swarbrick
Differentiation of stem cells into highly specialised cells requires gene expression changes brought about by remodelling of the chromatin architecture. During this lineage-commitment process, the majority of DNA needs to be packaged into inactive heterochromatin, allowing only a subset of regulatory elements to remain open and functionally required genes to be expressed. Epigenetic mechanisms such as DNA methylation, post-translational modifications to histone tails, and nucleosome positioning all potentially contribute to the changes in higher order chromatin structure during differentiation...
September 3, 2018: Breast Cancer Research: BCR
Iain R Hutcheson, Janice M Knowlden, Steve E Hiscox, Denise Barrow, Julia M W Gee, John F Robertson, Ian O Ellis, Robert I Nicholson
After the publication of this work [1], an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 4b. and Fig. 5d. Images of the ERK1/2 blots were accidentally duplicated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2 was mistakenly cropped out of the final image. The original blot for Fig. 4b., "total EGFR" (or lane 2) is shown below to avoid any misunderstanding of the data. We apologize for this error, which did not affect any of the interpretations or conclusions of the article.
August 30, 2018: Breast Cancer Research: BCR
Raquel Santana da Cruz, Elissa J Carney, Johan Clarke, Hong Cao, M Idalia Cruz, Carlos Benitez, Lu Jin, Yi Fu, Zuolin Cheng, Yue Wang, Sonia de Assis
BACKGROUND: While many studies have shown that maternal factors in pregnancy affect the cancer risk for offspring, few studies have investigated the impact of paternal exposures on their progeny's risk of this disease. Population studies generally show a U-shaped association between birthweight and breast cancer risk, with both high and low birthweight increasing the risk compared with average birthweight. Here, we investigated whether paternal malnutrition would modulate the birthweight and later breast cancer risk of daughters...
August 30, 2018: Breast Cancer Research: BCR
Mao Yang, Xiaobin Yu, Xuesen Li, Bo Luo, Wenli Yang, Yan Lin, Dabing Li, Zhonglin Gan, Jianming Xu, Tao He
BACKGROUND: Although ductal carcinoma in situ (DCIS) is a non-invasive breast cancer, many DCIS lesions may progress to invasive cancer and the genes and pathways responsible for its progression are largely unknown. FGFR1 plays an important role in cell proliferation, differentiation and carcinogenesis. The purpose of this study is to examine the roles of FGFR1 signaling in gene expression, cell proliferation, tumor growth and progression in a non-invasive DCIS model. METHODS: DCIS...
August 15, 2018: Breast Cancer Research: BCR
Asra N Shaik, Julie J Ruterbusch, Eman Abdulfatah, Resha Shrestha, M H D Fayez Daaboul, Visakha Pardeshi, Daniel W Visscher, Sudeshna Bandyopadhyay, Rouba Ali-Fehmi, Michele L Cote
BACKGROUND: Fibroadenomas are common benign breast lesions, and studies of European American women indicate a persistent, increased risk of breast cancer after diagnosing a fibroadenoma on biopsy. This association has not been independently assessed in African American women, despite reports that these women are more likely to present with fibroadenomas. METHODS: The study cohort included 3853 African American women with a breast biopsy completed between 1997 and 2010 in metropolitan Detroit...
August 9, 2018: Breast Cancer Research: BCR
Takuya Osada, Zachary C Hartman, Junping Wei, Gangjun Lei, Amy C Hobeika, William R Gwin, Marcio A Diniz, Neil Spector, Timothy M Clay, Wei Chen, Michael A Morse, H Kim Lyerly
BACKGROUND: Upregulation of human epidermal growth factor receptor 3 (HER3) is a major mechanism of acquired resistance to therapies targeting its heterodimerization partners epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), but also exposes HER3 as a target for immune attack. We generated an adenovirus encoding full length human HER3 (Ad-HER3) to serve as a cancer vaccine. Previously we reported the anti-tumor efficacy and function of the T cell response to this vaccine...
August 9, 2018: Breast Cancer Research: BCR
Cecilia W Huo, Prue Hill, Grace Chew, Paul J Neeson, Heloise Halse, Elizabeth D Williams, Michael A Henderson, Erik W Thompson, Kara L Britt
BACKGROUND: Epidemiological studies have consistently shown that increased mammographic density (MD) is a strong risk factor for breast cancer. We previously observed an elevated number of vimentin+ /CD45+ leukocytes in high MD (HMD) epithelium. In the present study, we aimed to investigate the subtypes of immune cell infiltrates in HMD and low MD (LMD) breast tissue. METHODS: Fifty-four women undergoing prophylactic mastectomy at Peter MacCallum Cancer Centre or St...
August 9, 2018: Breast Cancer Research: BCR
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"